HOSPITALITY
Anupam Rasayan Buys Remaining 47.95% Stake In Bliss GVS Pharma
Anupam Rasayan India Ltd, a specialty chemicals manufacturer, has completed the acquisition of the remaining 47.95% stake in listed pharmaceutical company Bliss GVS Pharma Ltd for ₹162.74 crore. The company acquired 5,09,84,595 equity shares of Bliss GVS Pharma, representing 47.95% of its share capital at ₹723.2883 per share. Following the acquisition, Anupam Rasayan and the […]
CW Bureau
·
Sep 29, 2026
GENERAL
Morepen Labs Files First ANDA, Eyes US Market With Sitagliptin Tablets
Morepen Laboratories Ltd has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitagliptin tablets USP in 25 mg, 50 mg and 100 mg strengths, marking the company’s entry into integrated finished dosage development and US regulatory filings. The submission expands Morepen’s established active pharmaceutical ingredient (API) […]
CW Bureau
·
Sep 28, 2026
GENERAL
Morepen Completes 1st Phase of API, CDMO Expansion Ahead Of Schedule
Morepen Laboratories has completed the first phase of its manufacturing capacity expansion programme ahead of schedule, increasing its installed reactor capacity for active pharmaceutical ingredients (API) and contract development and manufacturing organisation (CDMO) operations from 535 KL to 614 KL. The capacity addition is expected to strengthen Morepen Laboratories’ manufacturing readiness as the company scales […]
CW Bureau
·
Sep 7, 2026
GENERAL
Gland Pharma Signs MSA With Global Pharma Major For Sterile Injectables
Gland Pharma Ltd has entered into a strategic manufacturing and supply agreement (MSA) with a leading global pharmaceutical company for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for international markets. The agreement strengthens Gland Pharma’s position as an integrated end-to-end contract development and manufacturing organisation (CDMO), covering multiple products […]
CW Bureau
·
Aug 9, 2026
GENERAL
Gland Pharma Partners With Neuland Labs To Expand Sterile API Capacity
Gland Pharma and Neuland Laboratories have entered into a long-term strategic contract development and manufacturing organisation (CDMO) partnership to strengthen their presence in the fast-growing sterile active pharmaceutical ingredient (API) segment. As part of the collaboration, Gland Pharma will establish a dedicated sterile manufacturing suite for APIs used in microparticle depot products at its JNPC […]
CW Bureau
·
Aug 5, 2026
GENERAL
Zydus Lifesciences To Invest $20 Mn In Sri Lanka Pharma Production JV
Zydus Lifesciences Ltd, an innovation-driven global lifesciences company, has entered into a share subscription and shareholders’ agreement with Sunshine Healthcare Lanka Ltd to establish a pharmaceutical manufacturing facility in Sri Lanka with an investment of $20 million. The joint venture, Zydus Sunshine Lifesciences Pvt Ltd, will be set up at the Board of Investment zone […]
CW Bureau
·
Jun 26, 2026
GENERAL
Shilpa Biologicals Commissions ADC Drug Substance Manufacturing Unit
Shilpa Biologicals Ltd, a material subsidiary of Shilpa Medicare Ltd, has commissioned a Good Manufacturing Practice (GMP)-compliant Antibody-Drug Conjugate (ADC) manufacturing facility designed to meet global regulatory standards. The facility is fully operational, with GMP qualification protocols currently underway, paving the way for commercial-scale operations. Integrated ADC capabilities With the commissioning of the facility, Shilpa […]
CW Bureau
·
Jun 24, 2026
GENERAL
Sun Pharma Bets On R&D, Compliance Upgrades To Speed Up Growth Engine
Sun Pharmaceutical Industries is sharpening its focus on research and development, regulatory compliance, and manufacturing capabilities as it targets high single-digit consolidated revenue growth in FY27, Chairman Dilip Shanghvi said during the company’s latest earnings call. The pharmaceutical major continues to invest heavily in strengthening both its global generics and innovative medicines businesses, with R&D […]
CW Bureau
·
May 30, 2026
